[{"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-001", "question": "A 45-year-old man with a history of relapsing-remitting multiple sclerosis presents with acute onset of bilateral leg weakness and urinary retention. MRI shows a new T2-hyperintense lesion at T10 with gadolinium enhancement. Despite high-dose intravenous methylprednisolone, symptoms worsen over 48 hours. CSF analysis reveals elevated IgG index and oligoclonal bands. What is the most appropriate next step in management?", "options": ["Initiate plasma exchange", "Administer rituximab", "Start fingolimod", "Perform lumbar puncture for repeat CSF analysis", "Switch to natalizumab"], "answer": "A", "answer_index": 0, "explanation": "Plasma exchange is the most appropriate next step for severe acute demyelinating attacks unresponsive to corticosteroids in multiple sclerosis, as it rapidly removes circulating autoantibodies and inflammatory mediators. Rituximab and natalizumab are disease-modifying therapies not indicated for acute management, while fingolimod is contraindicated in active inflammation; repeat CSF analysis is unnecessary with established diagnosis.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient with Relapsing-Remitting Multiple Sclerosis (RRMS) experiencing a severe acute relapse (transverse myelitis) that is refractory to high-dose corticosteroids (symptoms worsening despite treatment). Standard neurological guidelines (e.g., AAN) recommend Plasma Exchange (PLEX) as the second-line treatment for severe acute demyelinating attacks that fail to respond to corticosteroids. Therefore, Option A is the correct next step. Options B, C, and E represent Disease-Modifying Therapies (DMTs) used for long-term prevention of relapses, not for the acute management of an active, worsening attack. Option D is unnecessary as the diagnosis is established and CSF findings are already known. The item is medically accurate and logically sound with a unique best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient with Relapsing-Remitting Multiple Sclerosis (RRMS) experiencing a severe acute relapse (transverse myelitis) that is refractory to high-dose corticosteroids (symptoms worsening despite treatment). Standard neurological guidelines (e.g., AAN) recommend Plasma Exchange (PLEX) as the second-line treatment for severe acute demyelinating attacks that fail to respond to corticosteroids. Therefore, Option A is the correct next step. Options B, C, and E represent Disease-Modifying Therapies (DMTs) used for long-term prevention of relapses, not for the acute management of an active, worsening attack. Option D is unnecessary as the diagnosis is established and CSF findings are already known. The item is medically accurate and logically sound with a unique best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-002", "question": "A 62-year-old woman with incomplete tetraplegia from a C5 spinal cord injury undergoes inpatient rehabilitation. She develops orthostatic hypotension during tilt table training, with blood pressure dropping from 120/80 mmHg supine to 85/50 mmHg at 60 degrees. Heart rate increases minimally. Autonomic testing shows absent sympathetic skin response below the lesion. What is the most effective pharmacologic intervention to facilitate upright tolerance?", "options": ["Midodrine", "Fludrocortisone", "Propranolol", "Clonidine", "Ephedrine"], "answer": "A", "answer_index": 0, "explanation": "Midodrine, an alpha-1 agonist, is the most effective for neurogenic orthostatic hypotension in spinal cord injury by promoting vasoconstriction without significant supine hypertension risk. Fludrocortisone causes fluid retention but risks edema; propranolol and clonidine may worsen hypotension, while ephedrine is less selective and has more side effects.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes neurogenic orthostatic hypotension (nOH) in a patient with a high spinal cord injury (C5), evidenced by a significant blood pressure drop without compensatory tachycardia (blunted autonomic response). Among the options, Midodrine (A) and Fludrocortisone (B) are the primary pharmacologic treatments. Midodrine, an alpha-1 agonist, acts directly to increase vascular resistance and is particularly effective for acute management to facilitate rehabilitation activities (like tilt table training) due to its rapid onset (approx. 1 hour). Fludrocortisone acts primarily via volume expansion and takes days to weeks for maximal effect, making it less ideal for immediate facilitation of upright tolerance in this context. Propranolol and Clonidine would likely worsen hypotension. Ephedrine is less selective. Therefore, Midodrine is the single best answer. Note: The provided author rationale incorrectly states Midodrine has 'no significant supine hypertension risk'; supine hypertension is actually its primary dose-limiting side effect. However, the key itself is correct.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes neurogenic orthostatic hypotension (nOH) in a patient with a high spinal cord injury (C5), evidenced by a significant blood pressure drop without compensatory tachycardia (blunted autonomic response). Among the options, Midodrine (A) and Fludrocortisone (B) are the primary pharmacologic treatments. Midodrine, an alpha-1 agonist, acts directly to increase vascular resistance and is particularly effective for acute management to facilitate rehabilitation activities (like tilt table training) due to its rapid onset (approx. 1 hour). Fludrocortisone acts primarily via volume expansion and takes days to weeks for maximal effect, making it less ideal for immediate facilitation of upright tolerance in this context. Propranolol and Clonidine would likely worsen hypotension. Ephedrine is less selective. Therefore, Midodrine is the single best answer. Note: The provided author rationale incorrectly states Midodrine has 'no significant supine hypertension risk'; supine hypertension is actually its primary dose-limiting side effect. However, the key itself is correct.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-003", "question": "A 28-year-old woman presents with recurrent episodes of vertigo, tinnitus, and fluctuating hearing loss, now with superimposed gait instability. MRI reveals bilateral vestibular schwannomas and a spinal ependymoma. Genetic testing confirms NF2 mutation. She develops progressive bilateral facial weakness. What is the most appropriate targeted therapy to consider for tumor stabilization?", "options": ["Bevacizumab", "Everolimus", "Crizotinib", "Trametinib", "Sorafenib"], "answer": "A", "answer_index": 0, "explanation": "Bevacizumab, a VEGF inhibitor, is the most appropriate for NF2-associated schwannomas by reducing tumor vascularity and stabilizing growth, with evidence from clinical trials showing hearing preservation. Everolimus targets mTOR but lacks specificity for NF2; crizotinib, trametinib, and sorafenib are not indicated for this condition and target unrelated pathways.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). The vignette describes a classic case of Neurofibromatosis type 2 (NF2) characterized by bilateral vestibular schwannomas and a spinal ependymoma. The patient exhibits progressive neurological deficits (facial weakness), prompting consideration of medical therapy to stabilize the tumors. Bevacizumab (Option A), a monoclonal antibody against VEGF, is the most widely accepted and evidence-based systemic therapy for progressive NF2-associated vestibular schwannomas, particularly for tumor stabilization and hearing preservation in patients who are poor surgical candidates or to delay surgery. Trametinib (Option D) is a MEK inhibitor indicated for NF1-associated plexiform neurofibromas, not NF2. Everolimus (Option B) has been investigated for NF2 but demonstrated limited efficacy in clinical trials compared to bevacizumab. Options C and E are not standard treatments for this condition. The item is medically accurate, the distractors are distinct, and the key represents the current standard of care for medical management of this condition.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). The vignette describes a classic case of Neurofibromatosis type 2 (NF2) characterized by bilateral vestibular schwannomas and a spinal ependymoma. The patient exhibits progressive neurological deficits (facial weakness), prompting consideration of medical therapy to stabilize the tumors. Bevacizumab (Option A), a monoclonal antibody against VEGF, is the most widely accepted and evidence-based systemic therapy for progressive NF2-associated vestibular schwannomas, particularly for tumor stabilization and hearing preservation in patients who are poor surgical candidates or to delay surgery. Trametinib (Option D) is a MEK inhibitor indicated for NF1-associated plexiform neurofibromas, not NF2. Everolimus (Option B) has been investigated for NF2 but demonstrated limited efficacy in clinical trials compared to bevacizumab. Options C and E are not standard treatments for this condition. The item is medically accurate, the distractors are distinct, and the key represents the current standard of care for medical management of this condition.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-004", "question": "A 55-year-old man with diabetic amyotrophy presents for outpatient rehabilitation with severe proximal leg weakness and pain. Electromyography shows denervation in the L2-L4 myotomes. Despite optimized glycemic control, he has persistent muscle atrophy. What is the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy?", "options": ["Intravenous immunoglobulin", "Pyridostigmine", "Gabapentin", "Corticosteroids", "Plasmapheresis"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin has shown benefit in diabetic amyotrophy by modulating autoimmune-mediated nerve damage, leading to improved strength and pain control in refractory cases. Corticosteroids risk worsening diabetes; pyridostigmine is for myasthenia, gabapentin addresses pain but not weakness, and plasmapheresis lacks supporting evidence.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: N (No answer defensible). \\nVerdict: No defensible answer based on current medical consensus. \\n\\nThe question asks for the \\\"most evidence-based adjunctive therapy\\\" to enhance functional recovery (motor strength/reversal of atrophy) in diabetic amyotrophy. Current major guidelines and systematic reviews (e.g., Cochrane) conclude there is insufficient evidence to support the use of immunotherapies (IVIG, corticosteroids, plasmapheresis) for this condition. Diabetic amyotrophy is generally considered monophasic and self-limiting, treated with supportive care (pain management, glycemic control, PT). While IVIG is sometimes used off-label in refractory cases based on anecdotal or small-study data, labeling it the \\\"most evidence-based\\\" answer for a board exam is medically inaccurate and contradicts the standard of care, which emphasizes that no disease-modifying therapy has proven efficacy. Gabapentin (Option C) is evidence-based for pain but does not treat the underlying weakness or atrophy. Thus, no option fulfills the stem's criteria for an evidence-based functional recovery aid. \\n\\nMinimal fix: Change the question to ask about symptomatic management (keying Gabapentin) or rephrase to ask which therapy is 'investigational' or 'proposed based on inflammatory pathophysiology' (though still clinically controversial).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: N (No answer defensible). \nVerdict: No defensible answer based on current medical consensus. \n\nThe question asks for the \"most evidence-based adjunctive therapy\" to enhance functional recovery (motor strength/reversal of atrophy) in diabetic amyotrophy. Current major guidelines and systematic reviews (e.g., Cochrane) conclude there is insufficient evidence to support the use of immunotherapies (IVIG, corticosteroids, plasmapheresis) for this condition. Diabetic amyotrophy is generally considered monophasic and self-limiting, treated with supportive care (pain management, glycemic control, PT). While IVIG is sometimes used off-label in refractory cases based on anecdotal or small-study data, labeling it the \"most evidence-based\" answer for a board exam is medically inaccurate and contradicts the standard of care, which emphasizes that no disease-modifying therapy has proven efficacy. Gabapentin (Option C) is evidence-based for pain but does not treat the underlying weakness or atrophy. Thus, no option fulfills the stem's criteria for an evidence-based functional recovery aid. \n\nMinimal fix: Change the question to ask about symptomatic management (keying Gabapentin) or rephrase to ask which therapy is 'investigational' or 'proposed based on inflammatory pathophysiology' (though still clinically controversial).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}]